Protease inhibitors. Part 7: Inhibition of Clostridium histolyticum collagenase with sulfonylated derivatives of L-valine hydroxamate

European Journal of Pharmaceutical Sciences

Volumn 10, Issue 1, 2000, Pages 67-76

  Supuran, Claudiu T ^a   Scozzafava, Andrea ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Clostridium histolyticum; Collagenase; L Valine hydroxamate; Sulfonamide; Zinc metalloproteinase

Indexed keywords

AMINO ACID; COLLAGENASE; HYDROXAMIC ACID; MATRIX METALLOPROTEINASE INHIBITOR; SULFONAMIDE; VALINE; ZINC;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL INFECTION; CLOSTRIDIUM HISTOLYTICUM; ENZYME ACTIVITY; ENZYME BINDING; ENZYME INHIBITION; KERATITIS; NONHUMAN; PRIORITY JOURNAL;

HYDROXAMIC ACIDS; MICROBIAL COLLAGENASE; PROTEASE INHIBITORS; VALINE;

EID: 0034048903     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0928-0987(99)00090-1     Document Type: Article

References (45)

1. Babine R.E., Bender S.L. Molecular recognition of protein-ligand complexes: Applications to drug design. Chem. Rev. 97:1997;1359-1472.
2. Bartoloni A., Colao M.G., Orsi A., Dei R., Giganti E., Parenti F. In vitro activity of vancomycin, teicoplanin, daptomycin, ramoplanin, MDL 62873 and other agents against staphylococci, enterococci and Clostridium difficile. J. Antimicrob. Chemother. 26:1990;627-633.
3. Bihovsky R., Levinson B.L., Loewi R.C., Erhardt P.W., Polokoff M.A. Hydroxamic acids as potent inhibitors of endothelin-converting enzyme from human bronchiolar smooth muscle. J. Med. Chem. 38:1995;2119-2129.
4. Bond M.D., van Wart H.E. Purification and separation of individual collagenases of Clostridium histolyticum using red dye ligand chromatography. Biochemistry. 23:1984;3077-3085.
5. Bond M.D., van Wart H.E. Characterization of the individual collagenases from Clostridium histolyticum. Biochemistry. 23:1984;3085-3091.
6. Bottomley K.M., Johnson W.H., Walter D.S. Matrix metalloproteinase inhibitors in arthritis. J. Enzyme Inhib. 13:1998;79-101.
7. Bourdel E., Doulut S., Jarretou G., Labbe-Jullie C., Fehrentz J.A., Doumbia O., Kitabgi P., Martinez J. New hydroxamate inhibitors of neurotensin-degrading enzymes. Synthesis and enzyme active-site recognition. Int. J. Pept. Protein Res. 48:1996;148-155.
8. Dive V., Yiotakis A., Nicolaou A., Toma F. Inhibition of Clostridium histolyticum collagenases by phosphonamide peptide inhibitors. Eur. J. Biochem. 191:1990;685-693.
9. Dixon M. Determination of enzyme-inhibitor constants. Biochem. J. 55:1953;170-171.
10. Galardy R.E., Grobelny D. Inhibition of collagenase from Clostridium histolyticum by phosphoric and phosphonic amides. Biochemistry. 22:1983;4556-4561.
11. Graf von Roedern E., Brandstetter H., Engh R.A., Bode W., Grams F., Moroder L. Bis-substituted malonic acid hydroxamate derivatives as inhibitors of human neutrophil collagenase (MMP8). J. Med. Chem. 41:1998;3041-3047.
12. Grobelny D., Galardy R.E. Aldehyde and ketone substrate analogues inhibit collagenase of Clostridium histolyticum. Biochemistry. 24:1985;6145-6152.
13. Grobelny D., Poncz L., Galardy R.E. Inhibition of human skin fibroblast collagenase, thermolysin, and Pseudomonas aeruginosa elastase by peptide hydroxamic acids. Biochemistry. 31:1992;7152-7154.
14. Groneberg R.D., Burns C.J., Morrissette M.M., Ullrich J.W., Morris R.L., Darnbrough S., Djuric S.W., Condon S.M., McGeehan G.M., Labaudiniere R., Neuenschwander K., Scotese A.C., Kline J.A. Dual inhibition of phosphodiesterase 4 and matrix metalloproteinases by an (arylsulfonyl)hydroxamic acid template. J. Med. Chem. 42:1999;541-544.
15. Groos E.B. Krachmer J.H., Mannis M.J., Holland E.J. Cornea: Fundamentals of Cornea and External Disease. Vol. 6:1997;105-142 Mosby-Year Book, St. Louis, MO.
16. Harris R.B., Strong P.D., Wilson I.B. Dipeptide hydroxamates are good inhibitors of the angiotensin I-converting enzyme. Biochem. Biophys. Res. Commun. 116:1983;394-399.
17. Heinemann J.A. How antibiotics cause antibiotic resistance. Drug Discov. Today. 4:1999;72-79.
18. Hogg J.H., Ollmann I.R., Haeggstrom J.Z., Wetterholm A., Samuelsson B., Wong C.H. Amino hydroxamic acids as potent inhibitors of leukotriene A4 hydrolase. Bioorg. Med. Chem. 3:1995;1405-1415.
19. Jackmann J.E., Raetz C.R., Fierke C.A. UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase of Escherichia coli is a zinc metalloenzyme. Biochemistry. 38:1999;1902-1911.
20. Jeng A.Y., Chou M., Parker D.T. Sulfonamide-based hydroxamic acids as potent inhibitors of mouse macrophage metalloelastase. Bioorg. Med. Chem. Lett. 8:1998;897-902.
21. Johnson L.L., Dyer R., Hupe D.J. Matrix metalloproteinases. Curr. Opin. Chem. Biol. 2:1998;466-471.
22. Jung C.M., Matsushita O., Katayama S., Minami J., Sakurai J., Okabe A. Identification of metal ligands in the Clostridium histolyticum ColH collagenase. J. Bacteriol. 181:1999;2816-2822.
23. Kim D.H., Jin Y. First hydroxamate inhibitors of carboxypeptidase A. N-acyl-N-hydroxy-beta-phenylalanines. Bioorg. Med. Chem. Lett. 9:1999;691-696.
24. Krumme D., Wenzel H., Tschesche H. Hydroxamate derivatives of substrate-analogous peptides containing aminomalonic acid are potent inhibitors of matrix metalloproteinases. FEBS Lett. 436:1998;209-212.
25. Levy D.E., Lapierre F., Liang W., Ye W., Lange C.W., Li X., Grobelyn D., Casabonne M., Tyrrell D., Holme K., Nadzan A., Galardy R.E. Matrix metalloproteinase inhibitors: Structure-activity study. J. Med. Chem. 41:1998;199-223.
26. Lozonschi L., Sunamura M., Kobari M., Egawa S., Ding L., Matsuno S. Controlling tumor angiogenesis and metastasis of C26 murine colon adenocarcinoma by a new matrix metalloproteinase inhibitor, KB-R7785, in two tumor models. Cancer Res. 15:1999;1252-1258.
27. Matsushita O., Jung C.M., Minami J., Katayama S., Nishi N., Okabe A. A study of the collagen-binding domain of a 116-kDa Clostridium histolyticum collagenase. J. Biol. Chem. 273:1998;3643-3648.
28. Matsushita O., Jung C.M., Minami J., Katayama S., Minami J., Takashi Y., Okabe A. Gene duplication and multiplicity of collagenase in Clostridium histolyticum. J. Bacteriol. 181:1999;923-933.
29. Onishi H.R., Pelak B.A., Gerckens L.S., Silver L.L., Kahan F.M., Chen M.H., Patchett A.A., Galloway S.M., Hyland S.A., Anderson M.S., Raetz C.R. Antibacterial agents that inhibit lipid A biosynthesis. Science. 274:1996;980-982.
30. Rawlings N.D., Barrett A.J. Evolutionary families of metallopeptidases. Methods Enzymol. 248:1995;183-228.
31. Rood J.I. Virulence genes of Clostridium perfringens. Annu. Rev. Microbiol. 52:1998;333-360.
32. Schiff W.M., Speaker M.G., McCormick S.A. The collagen shield as a collagenase inhibitor and clinical indicator of collagenase activity on the ocular surface. CLAO J. 18:1992;59-63.
33. Scozzafava A., Menabuoni L., Mincione F., Briganti F., Mincione G., Supuran C.T. Carbonic anhydrase inhibitors. Synthesis of water-soluble, topically effective intraocular pressure-lowering aromatic/heterocyclic sulfonamides containing cationic or anionic moieties: Is the tail more important than the ring? J. Med. Chem. 42:1999;2641-2650.
34. Scozzafava A., Briganti F., Mincione G., Menabuoni L., Mincione F., Supuran C.T. Carbonic anhydrase inhibitors. Synthesis of water-soluble, amino-acyl/dipeptidyl sulfonamides possessing long-lasting intraocular pressure-lowering properties via the topical route. J. Med. Chem. 42:1999;3690-3700.
35. Scozzafava A., Supuran C.T. Carbonic anhydrase inhibitors. Arylsulfonylureido and arylureido-substituted aromatic and heterocyclic sulfonamides: towards selective inhibitors of carbonic anhydrase isozyme I. J. Enzyme Inhib. 14:1999;343-363.
36. Supuran C.T., Ilies M.A., Scozzafava A. Carbonic anhydrase inhibitors. Part 29. Interaction of isozymes I, II and IV with benzolamide-like derivatives. Eur. J. Med. Chem. 33:1998;739-751.
37. Supuran C.T., Scozzafava A., Jurca B.C., Ilies M.A. Carbonic anhydrase inhibitors. Part 49. Synthesis of substituted ureido- and thioureido derivatives of aromatic/heterocyclic sulfonamides with increased affinities for isozyme I. Eur. J. Med. Chem. 33:1998;83-93.
38. Supuran C.T., Scozzafava A., Menabuoni L., Mincione F., Briganti F., Mincione G. Carbonic anhydrase inhibitors. Part 71. Synthesis and ocular pharmacology of a new class of water-soluble, topically effective intraocular pressure lowering sulfonamides incorporating picolinoyl moieties. Eur. J. Pharm. Sci. 24:1999;317-328.
39. van Wart H.E., Steinbrink D.R. A continuous spectrophotometric assay for Clostridium histolyticum collagenase. Anal. Biochem. 113:1981;156-165.
40. Vencill C.F., Rasnick D., Crumley K.V., Nishino N., Powers J.C. Clostridium histolyticum collagenase: development of new thioester fluorogenic and depsipeptide substrates and new inhibitors. Biochemistry. 24:1985;3149-3157.
41. Wojtowicz-Praga S., Low J., Marshall J., Ness E., Dickson R., Barter J., Sale M., McCann P., Moore J., Cole A., Hawkins M.J. Phase I trial of a novel matrix metalloproteinase inhibitor batimastat (BB-94) in patients with advanced cancer. Invest. New Drugs. 14:1996;193-202.
42. Yamamoto M., Tsujishita H., Hori N., Ohishi Y., Inoue S., Ikeda S., Okada Y. Inhibition of membrane-type I matrix metalloproteinase by hydroxamate inhibitors: An examination of the subsite pocket. J. Med. Chem. 41:1998;1209-1217.
43. Yiotakis A., Dive V. New thiol inhibitor of Achromobacter iophagus collagenase. Specificity of the enzyme's S3′ subsite. Eur. J. Biochem. 160:1986;413-418.
44. Yiotakis A., Hatgiyannacou A., Dive V., Toma F. New thiol inhibitors of Clostridium histolyticum collagenase. Importance of the P3′ position. Eur. J. Biochem. 172:1988;761-766.
45. Yiotakis A., Lecoq A., Nicolaou A., Labadie J., Dive V. Phosphinic peptide analogues as potent inhibitors of Corynebacterium rathayii bacterial collagenase. Biochem. J. 303:1994;323-327.